Exact Sciences (NASDAQ: EXAS) reported Q3 EPS of ($0.21), $0.01 worse than the analyst estimate of ($0.20). Revenue for the quarter came in at $709 million versus the consensus estimate of $716.8 million.

GUIDANCE:

Exact Sciences sees FY2024 revenue of $2.73-2.75 billion, versus the consensus of $2.83 billion.

The Company has updated its full-year 2024 revenue and adjusted EBITDA guidance:

	Prior guidance		November 5 update
Total revenue	$2.810 - $2.850 billion		$2.730 - $2.750 billion
Screening	$2.155 - $2.175 billion		$2.080 - $2.095 billion
Precision Oncology	$655 - $675 million		$650 - $655 million
Adjusted EBITDA	$335 - $355 million		$310 - $320 million

For earnings history and earnings-related data on Exact Sciences (EXAS) click here.